Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up
The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks....
Gespeichert in:
| Veröffentlicht in: | Case Reports in Ophthalmology 2022-08, Vol.13 (2), p.663-670 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 670 |
|---|---|
| container_issue | 2 |
| container_start_page | 663 |
| container_title | Case Reports in Ophthalmology |
| container_volume | 13 |
| creator | García-Delpech, Salvador Udaondo, Patricia Fernández-Santodomingo, Alex Samir García-Teillard, Damian |
| description | The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery. |
| doi_str_mv | 10.1159/000525923 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9459538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A717634889</galeid><doaj_id>oai_doaj_org_article_036c48fe9f00400894b200f765b20936</doaj_id><sourcerecordid>A717634889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-4375f5e55f97f9f61361b79f11a1a1c24cb8fbb614ca4764ef25e36e56d50293</originalsourceid><addsrcrecordid>eNptkk1r3EAMhk1paUKaQ-89DOTSHJzOtz09FMLSTUJDUprt2YzHmt3Zej3OeJxl_0N_dGfrsDRQdJCQHr1ISFn2nuALQoT6hDEWVCjKXmXHREqWU6nU63_io-x0GNYJw0zRkoi32RGTRGKu6HH2-w7G4GPw_coZ9A2Cjr7XcbVDiwA6QoO2Lq7QwvfO6Bb9AOM3tet0F9H1uNEduoPwBOgq-G3C5tpEH9DHGXSwhLBx3flnNNMDoAcIDgb0EMdmN0ne-m6ZLxKE5r5t_Tb_2b_L3ljdDnD67E-yxfzrYnad395f3cwub3MjqIo5Z4WwAoSwqrDKSpLWqQtlCdHJDOWmLm1dS8KN5oXkYKkAJkHIRmCq2El2M8k2Xq-rPriNDrvKa1f9TfiwrHSIzrRQYSYNLy0oizHHuFS8phjbQorkFZNJ68uk1Y_1BhoDXQy6fSH6stK5VbX0T5XiQglWJoGzZ4HgH0cYYrX2Y-jS-hUtCKcl52Q_8sVELXWaynU2nUybZA1snPEdWJfylwUpJONluW84nxpM8MMQwB5GIrja_011-JvEfpjYXzqkqx3IQ_nsv-XZ_feJqPrGsj_RwMgN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2714284419</pqid></control><display><type>article</type><title>Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>García-Delpech, Salvador ; Udaondo, Patricia ; Fernández-Santodomingo, Alex Samir ; García-Teillard, Damian</creator><creatorcontrib>García-Delpech, Salvador ; Udaondo, Patricia ; Fernández-Santodomingo, Alex Samir ; García-Teillard, Damian</creatorcontrib><description>The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.</description><identifier>ISSN: 1663-2699</identifier><identifier>EISSN: 1663-2699</identifier><identifier>DOI: 10.1159/000525923</identifier><identifier>PMID: 36160492</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Case Report ; Case reports ; cenegermin ; Cornea ; Disease ; Fluorescein ; Growth factors ; Health aspects ; Inflammation ; Nerve growth factor ; neurotrophic keratopathy ; Patients ; recombinant human nerve growth factor ; Ulcers</subject><ispartof>Case Reports in Ophthalmology, 2022-08, Vol.13 (2), p.663-670</ispartof><rights>2022 The Author(s). Published by S. Karger AG, Basel</rights><rights>COPYRIGHT 2022 S. Karger AG</rights><rights>2022 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-4375f5e55f97f9f61361b79f11a1a1c24cb8fbb614ca4764ef25e36e56d50293</citedby><orcidid>0000-0002-5241-0066 ; 0000-0002-8697-9883</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459538/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459538/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>García-Delpech, Salvador</creatorcontrib><creatorcontrib>Udaondo, Patricia</creatorcontrib><creatorcontrib>Fernández-Santodomingo, Alex Samir</creatorcontrib><creatorcontrib>García-Teillard, Damian</creatorcontrib><title>Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up</title><title>Case Reports in Ophthalmology</title><addtitle>Case Rep Ophthalmol</addtitle><description>The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.</description><subject>Case Report</subject><subject>Case reports</subject><subject>cenegermin</subject><subject>Cornea</subject><subject>Disease</subject><subject>Fluorescein</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>Inflammation</subject><subject>Nerve growth factor</subject><subject>neurotrophic keratopathy</subject><subject>Patients</subject><subject>recombinant human nerve growth factor</subject><subject>Ulcers</subject><issn>1663-2699</issn><issn>1663-2699</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1r3EAMhk1paUKaQ-89DOTSHJzOtz09FMLSTUJDUprt2YzHmt3Zej3OeJxl_0N_dGfrsDRQdJCQHr1ISFn2nuALQoT6hDEWVCjKXmXHREqWU6nU63_io-x0GNYJw0zRkoi32RGTRGKu6HH2-w7G4GPw_coZ9A2Cjr7XcbVDiwA6QoO2Lq7QwvfO6Bb9AOM3tet0F9H1uNEduoPwBOgq-G3C5tpEH9DHGXSwhLBx3flnNNMDoAcIDgb0EMdmN0ne-m6ZLxKE5r5t_Tb_2b_L3ljdDnD67E-yxfzrYnad395f3cwub3MjqIo5Z4WwAoSwqrDKSpLWqQtlCdHJDOWmLm1dS8KN5oXkYKkAJkHIRmCq2El2M8k2Xq-rPriNDrvKa1f9TfiwrHSIzrRQYSYNLy0oizHHuFS8phjbQorkFZNJ68uk1Y_1BhoDXQy6fSH6stK5VbX0T5XiQglWJoGzZ4HgH0cYYrX2Y-jS-hUtCKcl52Q_8sVELXWaynU2nUybZA1snPEdWJfylwUpJONluW84nxpM8MMQwB5GIrja_011-JvEfpjYXzqkqx3IQ_nsv-XZ_feJqPrGsj_RwMgN</recordid><startdate>20220831</startdate><enddate>20220831</enddate><creator>García-Delpech, Salvador</creator><creator>Udaondo, Patricia</creator><creator>Fernández-Santodomingo, Alex Samir</creator><creator>García-Teillard, Damian</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5241-0066</orcidid><orcidid>https://orcid.org/0000-0002-8697-9883</orcidid></search><sort><creationdate>20220831</creationdate><title>Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up</title><author>García-Delpech, Salvador ; Udaondo, Patricia ; Fernández-Santodomingo, Alex Samir ; García-Teillard, Damian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-4375f5e55f97f9f61361b79f11a1a1c24cb8fbb614ca4764ef25e36e56d50293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>Case reports</topic><topic>cenegermin</topic><topic>Cornea</topic><topic>Disease</topic><topic>Fluorescein</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>Inflammation</topic><topic>Nerve growth factor</topic><topic>neurotrophic keratopathy</topic><topic>Patients</topic><topic>recombinant human nerve growth factor</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Delpech, Salvador</creatorcontrib><creatorcontrib>Udaondo, Patricia</creatorcontrib><creatorcontrib>Fernández-Santodomingo, Alex Samir</creatorcontrib><creatorcontrib>García-Teillard, Damian</creatorcontrib><collection>Karger Open Access</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Delpech, Salvador</au><au>Udaondo, Patricia</au><au>Fernández-Santodomingo, Alex Samir</au><au>García-Teillard, Damian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up</atitle><jtitle>Case Reports in Ophthalmology</jtitle><addtitle>Case Rep Ophthalmol</addtitle><date>2022-08-31</date><risdate>2022</risdate><volume>13</volume><issue>2</issue><spage>663</spage><epage>670</epage><pages>663-670</pages><issn>1663-2699</issn><eissn>1663-2699</eissn><abstract>The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>36160492</pmid><doi>10.1159/000525923</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5241-0066</orcidid><orcidid>https://orcid.org/0000-0002-8697-9883</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1663-2699 |
| ispartof | Case Reports in Ophthalmology, 2022-08, Vol.13 (2), p.663-670 |
| issn | 1663-2699 1663-2699 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9459538 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Karger Open Access |
| subjects | Case Report Case reports cenegermin Cornea Disease Fluorescein Growth factors Health aspects Inflammation Nerve growth factor neurotrophic keratopathy Patients recombinant human nerve growth factor Ulcers |
| title | Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A26%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurotrophic%20Keratopathy%20Treated%20with%20Topical%20Recombinant%20Human%20Nerve%20Growth%20Factor%20(Cenegermin):%20Case%20Series%20Study%20with%20Long-Term%20Follow-Up&rft.jtitle=Case%20Reports%20in%20Ophthalmology&rft.au=Garc%C3%ADa-Delpech,%20Salvador&rft.date=2022-08-31&rft.volume=13&rft.issue=2&rft.spage=663&rft.epage=670&rft.pages=663-670&rft.issn=1663-2699&rft.eissn=1663-2699&rft_id=info:doi/10.1159/000525923&rft_dat=%3Cgale_pubme%3EA717634889%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2714284419&rft_id=info:pmid/36160492&rft_galeid=A717634889&rft_doaj_id=oai_doaj_org_article_036c48fe9f00400894b200f765b20936&rfr_iscdi=true |